Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Real-time Estimate Cboe BZX
Other stock markets
 12:34:59 2024-06-03 pm EDT 		5-day change 1st Jan Change
2.185 USD +1.16% Intraday chart for Esperion Therapeutics, Inc. +4.52% -26.59%
May. 22 Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events CI
May. 20 Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The stock, which is currently worth 2024 to 0.58 times its sales, is clearly overvalued in comparison with peers.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ESPERION THERAPEUTICS, INC. Stock Esperion Therapeutics, Inc.
-26.59% 409M
D+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.59% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.34% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.88% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.22% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.31% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.47% 240B
B+
NOVARTIS AG Stock Novartis AG
+9.26% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 206B
A+
AMGEN INC. Stock Amgen Inc.
+5.98% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. Ratings Esperion Therapeutics, Inc.